國立虎尾科技大學 |

The Future of HIV-1 Therapeutics = Resistance Is Futile? /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	The Future of HIV-1 Therapeutics/ edited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman.
Reminder of title:	Resistance Is Futile? /
other author:	Torbett, Bruce E.
Description:	X, 254 p.online resource. :
Contained By:	Springer Nature eBook
Subject:	Drug resistance. -
Online resource:	https://doi.org/10.1007/978-3-319-18518-7
ISBN:	9783319185187

The Future of HIV-1 Therapeutics = Resistance Is Futile? /
The Future of HIV-1 TherapeuticsResistance Is Futile? /[electronic resource] :edited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman. - 1st ed. 2015. - X, 254 p.online resource. - Current Topics in Microbiology and Immunology,3890070-217X ;. - Current Topics in Microbiology and Immunology,387.

HIV Therapy Looking Towards the Future -- Computational challenges of structure-based approaches applied to HIV -- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 -- HIV-1 integrase multimerization as a therapeutic target -- Targeting HIV transcription: The quest for a functional cure -- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder -- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy -- The Triple Threat of HIV-1 Protease Inhibitors -- Illustrations of the HIV Life Cycle.

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.

ISBN: 9783319185187

Standard No.: 10.1007/978-3-319-18518-7doiSubjects--Topical Terms:

872072
Drug resistance.

LC Class. No.: QR177

Dewey Class. No.: 616.9041

The Future of HIV-1 Therapeutics = Resistance Is Futile? /
LDR:02731nam a22004095i 4500 001 966964
003 DE-He213
005 20200706045929.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319185187 $9 978-3-319-18518-7
024 7 $a 10.1007/978-3-319-18518-7 $2 doi
035 $a 978-3-319-18518-7
050 4 $a QR177
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 616.9041 $2 23
245 1 4 $a The Future of HIV-1 Therapeutics $h [electronic resource] : $b Resistance Is Futile? / $c edited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a X, 254 p. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Current Topics in Microbiology and Immunology, $x 0070-217X ; $v 389
505 0 $a HIV Therapy Looking Towards the Future -- Computational challenges of structure-based approaches applied to HIV -- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 -- HIV-1 integrase multimerization as a therapeutic target -- Targeting HIV transcription: The quest for a functional cure -- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder -- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy -- The Triple Threat of HIV-1 Protease Inhibitors -- Illustrations of the HIV Life Cycle.
520 $a This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.
650 0 $a Drug resistance. $3 872072
650 0 $a Virology. $3 644995
650 0 $a Infectious diseases. $3 1102043
650 1 4 $a Drug Resistance. $3 782695
650 2 4 $a Infectious Diseases. $3 668393
700 1 $a Torbett, Bruce E. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1262600
700 1 $a Goodsell, David S. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 897761
700 1 $a Richman, Douglas D. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 865576
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319185194
776 0 8 $i Printed edition: $z 9783319185170
776 0 8 $i Printed edition: $z 9783319374505
830 0 $a Current Topics in Microbiology and Immunology, $x 0070-217X ; $v 387 $3 1254330
856 4 0 $u https://doi.org/10.1007/978-3-319-18518-7
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)